SEC comment letter
Filing comparison
SEC staff questioned PTC THERAPEUTICS, INC.'s accounting for MD&A
Letter dated 2025-08-21; published on EDGAR 2026-02-11 — the SEC releases comment letters only after the review closes.
Please revise in subsequent filings to disclose the sales royalty percentage to a range within 10 percentage points pursuant to the NTU Licensing Agreement. Shiratori, page 26 2. Please revise future filings to disclose the total aggregate amount of milestone payments made to date and may be paid in the future pursuant to the Shiratori License Agreement. Intellectual Property Patents and trade secrets, page 28 We…
Evidence
- Direction
- staff to company
- Letter dated
- 2025-08-21
- Published on edgar
- 2026-02-11
- Reviewing
- PTC Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 Filed February 27, 2025 File No. 001-35969 Dear Pierre Gravier: We have reviewed your f
- Source
- SEC staff comment letter (UPLOAD)
- Topics
- MD&A
- Why
- SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.